WEHI-539

• Description:

  WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  Bcl-2 Family

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/WEHI-539.html

• Purity:

  95.05

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(C1=C(CCCOC2=CC=C(CN)C=C2)SC(C3=CC4=C(CCC/C4=N\NC5=NC(C=CC=C6)=C6S5)C=C3)=N1)=O

• Molecular Formula:

  C31H29N5O3S2

• Molecular Weight:

  583.72

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Lessene G, et al. Structure-guided design of a selective BCL-X (L) inhibitor. Nat Chem Biol. 2013 Jun;9 (6) :390-7.|[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Bcl-xL

• Citation 01:

  Am J Cancer Res. 2019 Dec 1;9 (12) :2580-2598.|Breast Cancer Res Treat. 2019 Feb;173 (3) :585-596.|Cancer Biology. 2020 May.|Cell Death Differ. 2014 Jul;21 (7) :1170-7. |Cell Death Differ. 2017 Jan;24 (1) :111-119. |Cell Death Dis. 2017 Dec 13;8 (12) :3216.|Cell Death Dis. 2023 Oct 28;14 (10) :705.|Cell. 2014 Dec 18;159 (7) :1549-62.|Clin Cancer Res. 2019 Dec 1;25 (23) :7139-7150. |J Ovarian Res. 2016 Apr 14;9 (1) :25. |Nat Commun. 2016 Mar 9;7:10916.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncol Rep. 2019 Dec;42 (6) :2416-2425.|Pharmacol Res. 2023 Jan:187:106628.|Acta Pharmacol Sin. 2024 Nov;45 (11) :2420-2431.|bioRxiv. 2023 Aug 5.|Blood. 2014 Dec 4;124 (24) :3587-96. |Cell Death Dis. 2018 Jan 19;9 (2) :42.|Cell Rep. 2023 Mar 30;42 (4) :112324.|Cell. 2014 Dec 18;159 (7) :1549-62.|Immunity. 2024 Jun 11;57 (6) :1289-1305.e9.|Int J Cancer. 2018 Feb 1;142 (3) :584-596.|Malays Appl Biol. (2020) 49 (1) : 193-197.|Methods Mol Biol. 2018:1711:351-398.|Mol Cancer Ther. 2025 Jul 10.|Nat Biotechnol. 2018 Feb;36 (2) :179-189.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Nat Chem Biol. 2022 Jun;18 (6) :615-624.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncotarget. 2018 May 25;9 (40) :26046-26063.|The Department of Medical Sciences, Harvard University. 2019 Dec.

• CAS Number:

  [1431866-33-9]